Aliases & Classifications for Morbid Obesity

MalaCards integrated aliases for Morbid Obesity:

Name: Morbid Obesity 37 12 28 14
Obesity, Morbid 41 69
Severe Obesity 12
Obesity Morbid 51

Classifications:



External Ids:

Disease Ontology 12 DOID:11981
ICD9CM 34 278.01
MeSH 41 D009767
NCIt 46 C34858
UMLS 69 C0028756

Summaries for Morbid Obesity

MalaCards based summary : Morbid Obesity, also known as obesity, morbid, is related to body mass index quantitative trait locus 14 and body mass index quantitative trait locus 9, and has symptoms including obesity, metabolically benign An important gene associated with Morbid Obesity is PPARG (Peroxisome Proliferator Activated Receptor Gamma), and among its related pathways/superpathways are Peptide ligand-binding receptors and Glucose / Energy Metabolism. The drugs Dexmedetomidine and Hydroxocobalamin have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and bone, and related phenotypes are adipose tissue and homeostasis/metabolism

Related Diseases for Morbid Obesity

Diseases related to Morbid Obesity via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 204)
# Related Disease Score Top Affiliating Genes
1 body mass index quantitative trait locus 14 32.2 FTO MC4R
2 body mass index quantitative trait locus 9 32.1 MC3R MC4R
3 gastroesophageal reflux 30.1 CCK GHRL PYY
4 liver disease 30.1 ADIPOQ ALB INS LEP
5 nonalcoholic steatohepatitis 30.1 ADIPOQ INS LEP RETN
6 acanthosis nigricans 30.0 ADIPOQ INS LEP
7 sleep disorder 29.6 CRP HCRT LEP
8 apnea, obstructive sleep 29.6 ADIPOQ CRP HCRT INS LEP
9 diabetes mellitus 29.4 ADIPOQ ADRB3 ALB CRP INS LEP
10 fatty liver disease 29.3 ADIPOQ INS LEP LEPR PPARG RETN
11 polycystic ovary syndrome 29.1 GHRL INS LEP
12 pancreatitis 29.0 CCK CRP LPL
13 acute pancreatitis 29.0 CCK CRP LPL
14 myocardial infarction 28.9 ADIPOQ ALB CRP GHRL INS RETN
15 sleep apnea 28.7 ADIPOQ CRP GHRL HCRT INS LEP
16 eating disorder 28.6 ADIPOQ CCK GHRL LEP LEPR MC4R
17 bulimia nervosa 2 28.5 ADIPOQ CCK GHRL LEP LEPR PYY
18 prader-willi syndrome 28.5 ADIPOQ CCK GHRL HCRT INS LEP
19 body mass index quantitative trait locus 11 26.0 ADIPOQ ADRB3 CCK CRP FABP2 FTO
20 diabetes mellitus, noninsulin-dependent 25.1 ADIPOQ ADRB3 ALB CRP FABP2 GHRL
21 morbid obesity and spermatogenic failure 12.4
22 leptin deficiency or dysfunction 11.6
23 leptin receptor deficiency 11.3
24 body mass index quantitative trait locus 8 11.0
25 body mass index quantitative trait locus 7 11.0
26 body mass index quantitative trait locus 12 11.0
27 body mass index quantitative trait locus 18 11.0
28 body mass index quantitative trait locus 4 11.0
29 body mass index quantitative trait locus 10 11.0
30 malignant otitis externa 10.5 CRP INS
31 lipodystrophy, familial partial, type 2 10.4 INS LEP
32 abdominal obesity-metabolic syndrome quantitative trait locus 2 10.4 CRP INS LEP
33 endocrine pancreas disease 10.4 ADIPOQ INS LEP
34 acquired generalized lipodystrophy 10.4 ADIPOQ LEP RETN
35 obesity-hypoventilation syndrome 10.4 ADIPOQ LEP RETN
36 idiopathic recurrent pericarditis 10.4 ADIPOQ LEP RETN
37 multiple symmetrical lipomatosis 10.4 ADIPOQ LEP RETN
38 coronary artery aneurysm 10.4 ADIPOQ LEP RETN
39 familial partial lipodystrophy 10.3 INS LEP PPARG
40 acalculous cholecystitis 10.3 CCK CRP
41 idiopathic edema 10.3 ADIPOQ INS PPARG
42 hyperuricemia 10.3 ADRB3 CRP INS
43 hyperthyroidism 10.3 GHRL INS LEP
44 autoinflammation, lipodystrophy, and dermatosis syndrome 10.3 ADIPOQ CRP PPARG
45 postgastrectomy syndrome 10.3 INS PYY
46 inherited metabolic disorder 10.3 ADIPOQ CRP INS LEP
47 mediastinitis 10.3 CRP INS
48 hyperinsulinism 10.2 GHRL INS LEP
49 pyuria 10.2 ALB CRP
50 urinary system disease 10.2 ALB CRP INS

Graphical network of the top 20 diseases related to Morbid Obesity:



Diseases related to Morbid Obesity

Symptoms & Phenotypes for Morbid Obesity

UMLS symptoms related to Morbid Obesity:


obesity, metabolically benign

MGI Mouse Phenotypes related to Morbid Obesity:

43 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 adipose tissue MP:0005375 10.39 INS LPL LEP MC3R MC4R LEPR
2 homeostasis/metabolism MP:0005376 10.38 INS LPL LEP MC3R MC4R LEPR
3 behavior/neurological MP:0005386 10.34 INS LEP MC3R MC4R LEPR PPARG
4 growth/size/body region MP:0005378 10.28 LEPR INS LPL LEP MC3R MC4R
5 endocrine/exocrine gland MP:0005379 10.16 LEPR INS LEP PPARG ADRB3 FTO
6 cardiovascular system MP:0005385 10.13 HCRT LEPR INS LPL LEP MC4R
7 immune system MP:0005387 10.07 LEPR INS MC3R LEP PPARG RETN
8 liver/biliary system MP:0005370 10.06 INS LPL LEP MC4R LEPR PPARG
9 muscle MP:0005369 9.86 LEPR INS LPL LEP PPARG ALB
10 neoplasm MP:0002006 9.63 LEPR LEP MC4R PPARG ALB ADIPOQ
11 renal/urinary system MP:0005367 9.61 LEPR INS LEP PPARG FTO ALB
12 skeleton MP:0005390 9.28 LEPR INS MC3R LEP MC4R PPARG

Drugs & Therapeutics for Morbid Obesity

Drugs for Morbid Obesity (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 336)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 5311068 56032 68602
2
Hydroxocobalamin Approved Phase 4,Phase 2,Phase 3 13422-51-0 5460373 44475014 11953898
3
Morphine Approved, Investigational Phase 4,Phase 2,Phase 3 57-27-2 5288826
4
Acetaminophen Approved Phase 4,Phase 3,Phase 1,Early Phase 1 103-90-2 1983
5
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
6
Dalteparin Approved Phase 4 9005-49-6
7
Heparin Approved, Investigational Phase 4,Phase 1,Phase 2 9005-49-6 46507594 772
8 Nadroparin Approved, Investigational Phase 4 9041-08-1
9
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
10
Rocuronium Approved Phase 4,Phase 2 119302-91-9, 143558-00-3 441290
11
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 2078-54-8 4943
12
Liraglutide Approved Phase 4 204656-20-2 44147092
13
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3 437-38-7 3345
14
Ketamine Approved, Vet_approved Phase 4,Phase 3 6740-88-1 3821
15
Methylene blue Approved, Investigational Phase 4,Phase 1,Phase 2 61-73-4
16
Micafungin Approved, Investigational Phase 4 235114-32-6 477468 3081921
17
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
18
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2 73590-58-6 4594
19
chenodeoxycholic acid Approved Phase 4,Phase 2,Phase 1 474-25-9 10133
20
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
21 Fondaparinux Approved, Investigational Phase 4,Phase 1 104993-28-4
22
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7 9579578 4594
23
Iron Approved Phase 4,Phase 2,Phase 3 7439-89-6 23925
24
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 3 76-42-6 5284603
25
Ibuprofen Approved Phase 4 15687-27-1 3672
26
Ropivacaine Approved Phase 4 84057-95-4 175805 71273
27
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
28
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
29
Octreotide Approved, Investigational Phase 4 83150-76-9 6400441 383414
30
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
31
Verapamil Approved Phase 4 52-53-9 2520
32
Amphotericin B Approved, Investigational Phase 4 1397-89-3 5280965 14956
33
Etidronic acid Approved Phase 4 2809-21-4, 7414-83-7 3305
34
Cyanocobalamin Approved, Nutraceutical Phase 4,Phase 2,Phase 3 68-19-9 44176380
35
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3 59-30-3 6037
36
Methylcobalamin Approved, Experimental, Investigational, Nutraceutical Phase 4,Phase 2,Phase 3 13422-55-4
37
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 68-26-8, 11103-57-4 445354
38 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2
39
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
40 Hormones Phase 4,Phase 2,Phase 3,Phase 1
41 Adrenergic Agents Phase 4,Phase 3,Phase 1
42 Adrenergic Agonists Phase 4
43 Adrenergic alpha-2 Receptor Agonists Phase 4
44 Adrenergic alpha-Agonists Phase 4
45 Analgesics Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
46 Analgesics, Non-Narcotic Phase 4,Phase 1,Early Phase 1
47 Central Nervous System Depressants Phase 4,Phase 2,Phase 3,Phase 1
48 Hypnotics and Sedatives Phase 4,Phase 2,Phase 3,Phase 1
49 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1
50 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 534)

# Name Status NCT ID Phase Drugs
1 Impact of the Preservation of the Gastric Antrum in the Technique of Sleeve Gastrectomy for the Treatment of the Morbid Obesity Unknown status NCT01550601 Phase 4
2 Pharmacokinetics of Dexmedetomidine in Morbid Obesity Unknown status NCT01864187 Phase 4 Dexmedetomidine
3 Vitamin Deficiencies and Suppletion in Morbid Obesity Unknown status NCT02270749 Phase 4 Hydroxocobalamin;FitForMe vitamin B12
4 Evaluation of the Effects of Laying Early a Gastric Band on the Prevention of Morbid Obesity Randomized Checked Against Standard Management of Obesity in This Population. Unknown status NCT01700738 Phase 4
5 VAS Correlation With BMI Unknown status NCT02017314 Phase 4 Morphine
6 Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Sleeve Gastrectomy Unknown status NCT00667706 Phase 4
7 Pharmacokinetics of Acetaminophen in Morbidly Obese Patients Unknown status NCT01764555 Phase 4 acetaminophen 2 g
8 CYP3A4 Metabolism Before and After Surgery Induced Weight Loss Using Midazolam as Model Drug Unknown status NCT01519726 Phase 4 Midazolam
9 Anti Xa Levels Under Two Different Regimens of Enoxaparin VTE Prophylaxis After Sleeve Gastrectomy for Morbid Obesity Unknown status NCT01970202 Phase 4 40mg Enoxaparin;60mg Enoxaparin
10 Banded Versus Conventional Laparoscopic Roux-en-Y (GABY) Unknown status NCT01015469 Phase 4
11 Prophylaxis of Venous Thromboembolism After Bariatric Surgery Unknown status NCT02295150 Phase 4 Nadroparin
12 Laparoscopic Bariatric Surgery: Impact of Deep Neuromuscular Block on Surgical Conditions Unknown status NCT02118844 Phase 4 rocuronium
13 Obesity Cohort : Medical Follow-up of Severe or Morbid Obese Patients Undergoing Bariatric Surgery Unknown status NCT02310178 Phase 4
14 Clinical Trial Between Laparoscopic Gastric Bypass and Laparoscopic Vertical Banded Gastroplasty for Morbid Obesity Completed NCT01639677 Phase 4
15 Post Implantation/Post Market Evaluation of the Swedish Adjustable Gastric Band Completed NCT00543140 Phase 4
16 Investigations on the Influence of Bariatric Surgery on the Metabolism and Absorption of Atorvastatin Completed NCT00331565 Phase 4
17 Micafungin Pharmacokinetics in Obese Patients Completed NCT03102658 Phase 4 Micafungin
18 Garcinia Mangostana Extracts in the Management of Weight Loss Completed NCT02823561 Phase 4
19 Population PK/PD of Propofol in the Morbidly Obese Patient Completed NCT00395681 Phase 4 Diprivan
20 Study to Compare the Bioavailability (Amount of Drug Reaching the Blood) of Omeprazole 20 mg Before and After Undergoing Surgery for Morbid Obesity Completed NCT03378960 Phase 4 Omeprazole 20mg
21 Effects of Bile Acids on GLP-1 Secretion After Roux-en-Y Gastric Bypass Completed NCT02340247 Phase 4 Ursodeoxycholic Acid;Chenodeoxycholic Acid
22 Fondaparinux Population Pharmacokinetic to Morbid Obese Patients in Post-operatory Bariatric Surgery Completed NCT01064596 Phase 4
23 Use Of Esomeprazole In Postoperative Bariatric Surgery Patients Users And Non-Users Of Nonsteroidal Anti-Inflammatory Drugs (NSAIDS) Completed NCT00608712 Phase 4 Esomeprazole
24 The Use of Liposomated Iron After Bariatric Surgery in Patients That Are Receiving Parentheral Therapy With Iron Completed NCT02390921 Phase 4 Fisiogen Ferro Forte;Venofer
25 A Trial of the Cost Effectiveness of IV Acetaminophen in Bariatric Surgery Completed NCT02233400 Phase 4 Acetaminophen
26 Comparisons of iv Ibuprofen and iv Paracetamol During Bariatric Surgery Completed NCT02778958 Phase 4 paracetamol;ibuprofen
27 Study to Evaluate Weight-based Enoxaparin Dosing in Obese Medical Patients at Risk for DVT Completed NCT00585182 Phase 4 Enoxaparin 0.5 mg/kg once daily
28 Dosing Obese With Noxafil® Under a Trial (DONUT) Recruiting NCT03246386 Phase 4 Posaconazole Injection [Noxafil] 300mg;Posaconazole Injection [Noxafil] 400mg
29 Preoperative Condition in Giant Obese Patients Recruiting NCT02616003 Phase 4 Liraglutide
30 Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot) Recruiting NCT02959853 Phase 4 Anastrazole
31 Aspiration Therapy in Asian Patients Recruiting NCT02881684 Phase 4
32 DPE Technique in Labor Epidural for Morbidly Obese Women Recruiting NCT03074695 Phase 4 Dural puncture epidural (DPE);Standard Epidural (EPL)
33 Effect of Bile Acids and Bile Acid Sequstrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass Recruiting NCT02952963 Phase 4 Chenodeoxycholic Acid;Colesevelam
34 Effects of Bile Acids and Bile Acid Sequestrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass Recruiting NCT02876484 Phase 4 Colesevelam;Chenodeoxycholic Acid
35 Effect of Laparoscopic Sleeve Gastrectomy in the Morbidly Obese, Kidney Transplant Candidate Recruiting NCT01913392 Phase 4
36 Ketamine for Pain Relief in Bariatric Surgery Recruiting NCT03052673 Phase 4 Fentanyl;ketamine
37 Omega-3 Fatty Acids in Bariatric Gastric Bypass Surgery: Effect on Liver Volume, Immune Response and Erythrocyte Function Active, not recruiting NCT02206256 Phase 4 Omega-3 fatty acid capsules
38 Surgical Conditions During Laparoscopic Bariatric Surgery Active, not recruiting NCT02703909 Phase 4 Rocuronium
39 Gut Hormones as Mediators of Different Weight Loss Responses After Roux-en-Y Gastric Bypass Active, not recruiting NCT02374632 Phase 4
40 Treatment of Hypoglycemia Following Gastric Bypass Surgery Enrolling by invitation NCT02527993 Phase 4 Glucobay (acarbose);Januvia (sitagliptin);Verapamil HEXAL (verapamil);Victoza (liraglutide);Signifor (pasireotide)
41 Liposomal Amphotericin B (AmBisome) Pharmacokinetics Given as a Single Intravenous Dose to Obese Patients (ASPEN) Not yet recruiting NCT02320604 Phase 4 Administration of study drug
42 Weight Loss With Risedronate for Bone Health Not yet recruiting NCT03411902 Phase 4 Risedronate Sodium 150 MG
43 Study of Proton Pump Inhibitors (PPI) to Prevent Strictures After Gastric Bypass Surgery Withdrawn NCT00361985 Phase 4 Esomeprazole;Esomeprazole
44 Laparoscopic Sleeve Gastrectomy Plus Weight Watchers vs. Weight Watchers Alone in Underserved Minority Women Withdrawn NCT01929850 Phase 4
45 Stapled vs Hand Sewn Anastomosis in Roux en Y Gastric Bypass for Morbid Obesity: Randomized Clinical Trial Unknown status NCT02077517 Phase 3
46 Sevoflurane Versus Intravenous Anaesthetic Agents in Morbid Obese Patients Unknown status NCT01279499 Phase 2, Phase 3 Sevoflurane;Sevoflurane;Propofol- Remifentanyl;Propofol, Remifentanyl
47 Transoral Gastroplasty for the Treatment of Morbid Obesity Unknown status NCT00661245 Phase 3
48 Comparative Study of Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade in Morbidly Obese Patients Unknown status NCT01629394 Phase 2, Phase 3 Sugammadex;Sugammadex;Neostigmine;Neostigmine;Sugammadex;Sugammadex;Neostigmine;Neostigmine
49 The Effects of Exenatide After Gastric Restriction Unknown status NCT00872378 Phase 2, Phase 3 Exenatide;Placebo
50 Ketamine in Bariatric Surgery Unknown status NCT01724983 Phase 3 ketamine;fentanyl

Search NIH Clinical Center for Morbid Obesity

Cochrane evidence based reviews: obesity, morbid

Genetic Tests for Morbid Obesity

Genetic tests related to Morbid Obesity:

# Genetic test Affiliating Genes
1 Morbid Obesity 28

Anatomical Context for Morbid Obesity

MalaCards organs/tissues related to Morbid Obesity:

38
Liver, Testes, Bone, Kidney, Brain, Thyroid, Lung

Publications for Morbid Obesity

Articles related to Morbid Obesity:

(show top 50) (show all 795)
# Title Authors Year
1
Prader-Willi syndrome and early-onset morbid obesity NIH rare disease consortium: A review of natural history study. ( 29271568 )
2018
2
Brown adipose tissue lipid metabolism in morbid obesity: Effect of bariatric surgery-induced weight loss. ( 29377423 )
2018
3
Is perceived intolerance to milk and wheat associated with the corresponding IgG and IgA food antibodies? A cross sectional study in subjects with morbid obesity and gastrointestinal symptoms. ( 29378512 )
2018
4
Cost-effectiveness analysis of bariatric surgery for morbid obesity in Belgium. ( 29271279 )
2018
5
Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity. ( 29335933 )
2018
6
Morbid obesity and type 2 diabetes alter intestinal fatty acid uptake and blood flow. ( 29352513 )
2018
7
Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss at 5 Years Among Patients With Morbid Obesity: The SLEEVEPASS Randomized Clinical Trial. ( 29340676 )
2018
8
Single Incision Versus Conventional Laparoscopic Sleeve Gastrectomy for Morbid Obesity: A Meta-Analysis. ( 29389227 )
2018
9
A Tuscan general with morbid obesity. ( 29404906 )
2018
10
Stomach Intestinal Pylorus-Sparing Surgery for Morbid Obesity. ( 29398898 )
2018
11
Remission of Sjogren's Syndrome after Roux-en-Y Gastric Bypass for Morbid Obesity. ( 29248981 )
2018
12
Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss in Patients With Morbid Obesity: The SM-BOSS Randomized Clinical Trial. ( 29340679 )
2018
13
Associations of Prepregnancy Morbid Obesity and Prenatal Depression with Gestational Weight Gain. ( 29298365 )
2018
14
Colon adenocarcinoma after jejunoileal bypass for morbid obesity. ( 29230281 )
2017
15
Letter in Reply to Arno et al. "Pharmacokinetics in Morbid Obesity: Influence of Two Bariatric Surgery Techniques on Paracetamol and Caffeine Metabolism". ( 28844097 )
2017
16
Epicardial fat thickness correlates with P-wave duration, left atrial size and decreased left ventricular systolic function in morbid obesity. ( 28739186 )
2017
17
Morbid obesity is not a contraindication to transport on extracorporeal support. ( 29253111 )
2017
18
The usage of fasting glucose and glycated hemoglobin for the identification of unknown type 2 diabetes in high risk patients with morbid obesity. ( 28715238 )
2017
19
Decreased serum glicentin concentration in patients with severe and morbid obesity. ( 28661200 )
2017
20
Zinc Deficiency after Gastric Bypass for Morbid Obesity: a Systematic Review. ( 27885534 )
2017
21
Pulse-contour derived cardiac output measurements in morbid obesity: influence of actual, ideal and adjusted bodyweight. ( 28822023 )
2017
22
Weighing the risks: Morbid obesity and diabetes are associated with increased risk of death on the liver transplant waiting list. ( 28727287 )
2017
23
Anastomotic Stricture Rates Following Roux-en-Y Gastric Bypass for Morbid Obesity: A Comparison Between Linear and Circular-Stapled Anastomosis. ( 29237132 )
2017
24
Socioeconomic inequality in morbid obesity with body mass index more than 40A kg/m<sup>2</sup>in the United States and England. ( 29349213 )
2017
25
Prevalence of Micronutrient Deficiency in Patients with Morbid Obesity Before Bariatric Surgery. ( 28849358 )
2017
26
Does Cardiorespiratory Fitness Attenuate the Adverse Effects of Severe/Morbid Obesity on Cardiometabolic Risk and Insulin Resistance in Children? A Pooled Analysis. ( 28939688 )
2017
27
One-Anastomosis Gastric Bypass Versus Sleeve Gastrectomy for Morbid Obesity: a Systematic Review and Meta-analysis. ( 28681256 )
2017
28
Laparoscopic Sleeve Gastrectomy for Morbid Obesity in Patients After Orthotopic Liver Transplant: a Matched Case-Control Study. ( 28766265 )
2017
29
Plasma concentrations of caspofungin in a critically ill patient with morbid obesity. ( 28764793 )
2017
30
Long-Term Follow-Up of Autonomic and Enteric Measures in Patients Undergoing Vertical Banded Gastroplasty for Morbid Obesity. ( 28912907 )
2017
31
HIV Infection Is Not a Contraindication to Laparoscopic Sleeve Gastrectomy for Morbid Obesity. ( 28842820 )
2017
32
MYC amplification in angiosarcomas arising in the setting of chronic lymphedema of morbid obesity. ( 27686553 )
2017
33
Homozygous mutation in<i>CEP19,</i>a gene mutated in morbid obesity, in Bardet-Biedl syndrome with predominant postaxial polydactyly. ( 29127258 )
2017
34
Intake of non-nutritive sweeteners is associated with an unhealthy lifestyle: a cross-sectional study in subjects with morbid obesity. ( 29299330 )
2017
35
Outcomes Experienced by Patients Presenting with Ventral Hernia and Morbid Obesity in a Surgical Clinic. ( 28822383 )
2017
36
Portomesenteric vein thrombosis after laparoscopic sleeve gastrectomy for morbid obesity. ( 28069786 )
2017
37
Removal notice to The relationship between primary cesarean delivery skin incision type and wound complicationsA inA women with morbid obesity: Am J Obstet Gynecol 2014;210:319.e1-4. ( 28648694 )
2017
38
Answer to the Letter to the Editor Concerning "Pharmacokinetics in Morbid Obesity: Influence of Two Bariatric Surgery Techniques on Paracetamol and Caffeine Metabolism". ( 28840448 )
2017
39
Morbid Obesity Does not Increase Morbidity or Mortality in Robotic Cardiac Surgery. ( 29232296 )
2017
40
Relationship between changes in hemoglobin glycosilated and improvement of body composition in patients with morbid obesity after tubular laparoscopic gastrectomy. ( 29292099 )
2017
41
Comparative Effectiveness of Laparoscopic Sleeve Gastrectomy on Morbidly Obese, Super-Obese, and Super-Super Obese Patients for the Treatment of Morbid Obesity. ( 29235011 )
2017
42
Prevalence and predictors of irritable bowel syndrome in patients with morbid obesity: a cross-sectional study. ( 28680646 )
2017
43
Folate and vitamin B12 status is associated with insulin resistance and metabolic syndrome in morbid obesity. ( 28780990 )
2017
44
Modulation of SHBG binding to testosterone and estradiol by sex and morbid obesity. ( 28077498 )
2017
45
Effect of Weight Loss after Bariatric Surgery on Thyroid-Stimulating Hormone Levels in Patients with Morbid Obesity and Normal Thyroid Function. ( 28725979 )
2017
46
Relative prosthesis-patient mismatch after transcatheter aortic valve replacement: The impact of morbid obesity. ( 27566959 )
2016
47
The impact of morbid obesity on resource utilization after renal transplantation. ( 27574775 )
2016
48
Update on Treatment ofA Morbid Obesity withA Adjustable Gastric Banding. ( 27473802 )
2016
49
Morbid obesity is an independent risk factor forA postoperative renal dysfunction in young adults: a review of the American College ofA Surgeons National Surgical Quality Improvement Program database. ( 26941003 )
2016
50
Morbid obesity and outcome of ectopic pregnancy following capped single-dose regimen methotrexate. ( 27844211 )
2016

Variations for Morbid Obesity

ClinVar genetic disease variations for Morbid Obesity:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 PPARG NM_138712.3(PPARG): c.254C> A (p.Pro85Gln) single nucleotide variant Pathogenic rs1800571 GRCh37 Chromosome 3, 12422848: 12422848

Expression for Morbid Obesity

LifeMap Discovery
Genes differentially expressed in tissues of Morbid Obesity patients vs. healthy controls: 35
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 GAPDH glyceraldehyde-3-phosphate dehydrogenase Skeletal Muscle - 5.09 0.006
2 SLN sarcolipin Skeletal Muscle - 4.64 0.007
Search GEO for disease gene expression data for Morbid Obesity.

Pathways for Morbid Obesity

Pathways related to Morbid Obesity according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.38 ADRB3 CCK GHRL HCRT LEP LEPR
2 12.31 ADIPOQ FTO INS PPARG
3
Show member pathways
12.22 ADIPOQ INS LEP LEPR PPARG
5 11.55 INS LPL PPARG
6 11.51 ADIPOQ LEP LEPR
7 11.35 INS LEP LEPR
8 11.34 ADIPOQ INS LEP LPL PPARG
9 11.31 ADIPOQ FABP2 LPL PPARG
10 11.22 ADIPOQ INS LEP LPL PPARG RETN
11
Show member pathways
11.09 CRP LEP LEPR
12 10.94 ADIPOQ LEP PPARG
13 10.84 ADIPOQ LEP PPARG

GO Terms for Morbid Obesity

Cellular components related to Morbid Obesity according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.65 ADIPOQ ALB CCK CRP GHRL INS
2 extracellular region GO:0005576 9.4 ADIPOQ ALB CCK CRP GHRL HCRT

Biological processes related to Morbid Obesity according to GeneCards Suite gene sharing:

(show all 38)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of MAPK cascade GO:0043410 9.84 ADRB3 INS LEP
2 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.83 ADIPOQ CCK INS
3 response to nutrient GO:0007584 9.83 ADIPOQ LEP PPARG
4 response to insulin GO:0032868 9.79 LEP MC4R RETN
5 regulation of blood pressure GO:0008217 9.78 LEP MC3R PPARG
6 glucose metabolic process GO:0006006 9.78 ADIPOQ GHRL INS LEP
7 adenylate cyclase-activating G-protein coupled receptor signaling pathway GO:0007189 9.77 ADRB3 MC3R MC4R
8 response to nutrient levels GO:0031667 9.75 ADIPOQ GHRL LEP
9 adenylate cyclase-modulating G-protein coupled receptor signaling pathway GO:0007188 9.74 ADRB3 MC3R MC4R
10 feeding behavior GO:0007631 9.71 HCRT MC4R PYY
11 response to cold GO:0009409 9.7 ADRB3 LPL PPARG
12 negative regulation of vascular smooth muscle cell proliferation GO:1904706 9.68 ADIPOQ PPARG
13 positive regulation of cellular protein metabolic process GO:0032270 9.67 ADIPOQ INS
14 fatty acid oxidation GO:0019395 9.67 ADIPOQ PPARG
15 regulation of fat cell differentiation GO:0045598 9.67 LEP PPARG
16 temperature homeostasis GO:0001659 9.67 ADRB3 FTO HCRT
17 positive regulation of insulin receptor signaling pathway GO:0046628 9.66 INS LEP
18 sexual reproduction GO:0019953 9.65 LEP LEPR
19 glucose homeostasis GO:0042593 9.65 ADIPOQ INS LEP LEPR PPARG
20 negative regulation of blood vessel diameter GO:0097756 9.64 CRP INS
21 adult feeding behavior GO:0008343 9.64 GHRL LEP
22 negative regulation of lipid storage GO:0010888 9.63 CRP LEP
23 leptin-mediated signaling pathway GO:0033210 9.63 LEP LEPR
24 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.63 ADIPOQ CRP PPARG
25 negative regulation of appetite GO:0032099 9.62 CCK LEP
26 diet induced thermogenesis GO:0002024 9.62 ADRB3 MC4R
27 negative regulation of gluconeogenesis GO:0045721 9.61 ADIPOQ INS LEPR
28 regulation of bone remodeling GO:0046850 9.59 LEP LEPR
29 negative regulation of acute inflammatory response GO:0002674 9.58 INS PPARG
30 regulation of brown fat cell differentiation GO:0090335 9.56 FTO LEP
31 regulation of receptor activity GO:0010469 9.56 ADIPOQ CCK GHRL HCRT INS LEP
32 regulation of metabolic process GO:0019222 9.55 LEP MC4R
33 regulation of feeding behavior GO:0060259 9.54 LEPR MC3R MC4R
34 bone growth GO:0098868 9.51 LEP LEPR
35 negative regulation of feeding behavior GO:2000252 9.5 INS MC4R RETN
36 eating behavior GO:0042755 9.46 ADRB3 CCK HCRT LEP
37 energy reserve metabolic process GO:0006112 8.92 ADRB3 LEP LEPR MC4R
38 G-protein coupled receptor signaling pathway GO:0007186 10.06 ADRB3 CCK GHRL HCRT INS MC3R

Molecular functions related to Morbid Obesity according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.85 ADIPOQ ALB CRP INS LEPR PPARG
2 neuropeptide binding GO:0042923 9.4 MC3R MC4R
3 fatty acid binding GO:0005504 9.32 ALB FABP2
4 melanocortin receptor activity GO:0004977 9.26 MC3R MC4R
5 hormone activity GO:0005179 9.17 ADIPOQ CCK GHRL INS LEP PYY
6 melanocyte-stimulating hormone receptor activity GO:0004980 9.16 MC3R MC4R
7 neuropeptide hormone activity GO:0005184 9.13 CCK HCRT PYY

Sources for Morbid Obesity

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....